Explore more
News
British pharmaceutical giant GSK on Wednesday said it will buy efimosfermin, a phase III-ready potential specialty medicine ...
Belrestotug showed underwhelming efficacy outcomes in mid-stage studies of non-small cell lung cancer and head and neck ...
Under the agreement to acquire Boston Pharmaceuticals' lead asset Efimosfermin, GSK will pay $1.2 billion upfront followed by ...
Britain's GSK and drug developer iTeos Therapeutics said on Tuesday they have stopped developing an experimental lung cancer ...
The up move in the GSK Pharma share price came after the company posted a healthy March quarter of financial year 2025 ...
GSK has stopped development of anti-TIGIT antibody belrestotug. | GSK has stopped development of anti-TIGIT antibody ...
GSK PLC closed 25.53% below its 52-week high of £18.24, which the company reached on May 16th.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback